68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy

OBJECTIVEProstate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk stratification tool for Asian men with rapid biochemical recurrence (BCR) following radical prostatectomy (RadP). This study aims to assess the detection r...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & medicine Vol. 16; no. 1; pp. 157 - 166
Main Authors Tan, Janice S H, Goh, Charles X Y, Koh, Yen Sin, Li, Youquan, Tuan, Jeffrey K L, Chua, Eu Tiong, Tan, Terence W K, Wang, Michael L C, Lee, Lui Shiong, Tay, Kae Jack, Kanesvaran, Ravindran, Toh, Chee Keong, Tong, Aaron K T, Lam, Winnie W C, Chua, Melvin L K
Format Journal Article
LanguageEnglish
Published Tianjing China Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610%Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610 01.02.2019
Department of Surgery, Sengkang General Hospital, Singapore 544886%Department of Urology, Singapore General Hospital, Singapore 169610%Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Department of Urology, Singapore General Hospital, Singapore 169610
Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore
Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
Division of Medical Oncology, National Cancer Centre Singapore,Singapore 169610%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
Chinese Anti-Cancer Association
China Anti-Cancer Association
Subjects
Online AccessGet full text

Cover

Loading…
Abstract OBJECTIVEProstate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk stratification tool for Asian men with rapid biochemical recurrence (BCR) following radical prostatectomy (RadP). This study aims to assess the detection rate of 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for diagnosis of clinical recurrence and as a treatment decision making tool in Asian patients with BCR post-RadP. METHODS68Ga PSMA-PET and CT body with/without bone scan [conventional workup (CWU)] were performed in 55 Asian patients with BCR within 36 months post-RadP. Two blinded reviewers assessed the images. Detection rates of 68Ga PSMA-PET/CT were evaluated, and impact on management was reviewed by comparison with CWU. RESULTSMedian time to BCR post-RadP was 8.1 months. Detection rate for 68Ga PSMA-PET/CT was 80% (44/55). A positive scan was significantly associated with increasing prostate-specific antigen (PSA) level [odds ratio (OR) = 1.13 (95% CI 1.05-1.30), P = 0.017], but not with higher Gleason grade or shorter PSA doubling time. Compared to CWU, 68Ga PSMA-PET/CT detected an additional 106 lesions in 33/44 patients with a positive scan, resulting in a change in management in 25/44 (56.8%) patients: 10 to hormonal therapy (HT) and whole pelvis radiotherapy (RT) in addition to bed RT, and 15 to palliative HT alone. CONCLUSIONSIn the present report, we demonstrated the diagnostic and treatment decision utility of 68Ga PSMA-PET/CT in Asian men with rapid BCR. Detection of small volume nodal and systemic recurrences at low PSA levels (< 1.0 ng/mL) highlights the role of the tool in assigning patients to treatment intensification with HT-RT or palliative HT in polymetastatic disease.
AbstractList Objective Prostate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk stratification tool for Asian men with rapid biochemical recurrence (BCR) following radical prostatectomy (RadP). This study aims to assess the detection rate of 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for diagnosis of clinical recurrence and as a treatment decision making tool in Asian patients with BCR post-RadP.Methods 68Ga PSMA-PET and CT body with/without bone scan [conventional workup (CWU)] were performed in 55 Asian patients with BCR within 36 months post-RadP. Two blinded reviewers assessed the images. Detection rates of 68Ga PSMA-PET/CT were evaluated, and impact on management was reviewed by comparison with CWU. Results Median time to BCR post-RadP was 8.1 months. Detection rate for 68Ga PSMA-PET/CT was 80% (44/55). A positive scan was significantly associated with increasing prostate-specific antigen (PSA) level [odds ratio (OR) = 1.13 (95% CI 1.05–1.30), P = 0.017], but not with higher Gleason grade or shorter PSA doubling time. Compared to CWU, 68Ga PSMA-PET/CT detected an additional 106 lesions in 33/44 patients with a positive scan, resulting in a change in management in 25/44 (56.8%) patients: 10 to hormonal therapy (HT) and whole pelvis radiotherapy (RT) in addition to bed RT, and 15 to palliative HT alone. Conclusions In the present report, we demonstrated the diagnostic and treatment decision utility of 68Ga PSMA-PET/CT in Asian men with rapid BCR. Detection of small volume nodal and systemic recurrences at low PSA levels (< 1.0 ng/mL) highlights the role of the tool in assigning patients to treatment intensification with HT-RT or palliative HT in polymetastatic disease.
Objective:Prostate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts.There is no risk stratification tool for Asian men with rapid biochemical recurrence (BCR) following radical prostatectomy (RadP).This study aims to assess the detection rate of 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for diagnosis of clinical recurrence and as a treatment decision making tool in Asian patients with BCR post-RadP.Methods:68Ga PSMA-PET and CT body with/without bone scan [conventional workup (CWU)] were performed in 55 Asian patients with BCR within 36 months post-RadP.Two blinded reviewers assessed the images.Detection rates of 68Ga PSMA-PET/CT were evaluated,and impact on management was reviewed by comparison with CWU.Results:Median time to BCR post-RadP was 8.1 months.Detection rate for 68Ga PSMA-PET/CT was 80% (44/55).A positive scan was significantly associated with increasing prostate-specific antigen (PSA) level [odds ratio (OR) =1.13 (95% CI 1.05-1.30),P =0.017],but not with higher Gleason grade or shorter PSA doubling time.Compared to CWU,68Ga PSMA-PET/CT detected an additional 106 lesions in 33/44 patients with a positive scan,resulting in a change in management in 25/44 (56.8%) patients:10 to hormonal therapy (HT) and whole pelvis radiotherapy (RT) in addition to bed RT,and 15 to palliative HT alone.Conclusions:In the present report,we demonstrated the diagnostic and treatment decision utility of 68Ga PSMA-PET/CT in Asian men with rapid BCR.Detection of small volume nodal and systemic recurrences at low PSA levels (< 1.0 ng/mL) highlights the role of the tool in assigning patients to treatment intensification with HT-RT or palliative HT in polymetastatic disease.
OBJECTIVEProstate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk stratification tool for Asian men with rapid biochemical recurrence (BCR) following radical prostatectomy (RadP). This study aims to assess the detection rate of 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT) for diagnosis of clinical recurrence and as a treatment decision making tool in Asian patients with BCR post-RadP. METHODS68Ga PSMA-PET and CT body with/without bone scan [conventional workup (CWU)] were performed in 55 Asian patients with BCR within 36 months post-RadP. Two blinded reviewers assessed the images. Detection rates of 68Ga PSMA-PET/CT were evaluated, and impact on management was reviewed by comparison with CWU. RESULTSMedian time to BCR post-RadP was 8.1 months. Detection rate for 68Ga PSMA-PET/CT was 80% (44/55). A positive scan was significantly associated with increasing prostate-specific antigen (PSA) level [odds ratio (OR) = 1.13 (95% CI 1.05-1.30), P = 0.017], but not with higher Gleason grade or shorter PSA doubling time. Compared to CWU, 68Ga PSMA-PET/CT detected an additional 106 lesions in 33/44 patients with a positive scan, resulting in a change in management in 25/44 (56.8%) patients: 10 to hormonal therapy (HT) and whole pelvis radiotherapy (RT) in addition to bed RT, and 15 to palliative HT alone. CONCLUSIONSIn the present report, we demonstrated the diagnostic and treatment decision utility of 68Ga PSMA-PET/CT in Asian men with rapid BCR. Detection of small volume nodal and systemic recurrences at low PSA levels (< 1.0 ng/mL) highlights the role of the tool in assigning patients to treatment intensification with HT-RT or palliative HT in polymetastatic disease.
Author Lam, Winnie W C
Tong, Aaron K T
Chua, Eu Tiong
Lee, Lui Shiong
Tan, Terence W K
Goh, Charles X Y
Wang, Michael L C
Chua, Melvin L K
Kanesvaran, Ravindran
Toh, Chee Keong
Koh, Yen Sin
Tay, Kae Jack
Li, Youquan
Tuan, Jeffrey K L
Tan, Janice S H
AuthorAffiliation Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610%Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610;Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610;Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Department of Urology, Singapore General Hospital, Singapore 169610;Department of Surgery, Sengkang General Hospital, Singapore 544886%Department of Urology, Singapore General Hospital, Singapore 169610%Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857;Division of Medical Oncology, National Cancer Centre Singapore,Singapore 169610%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610;Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857;Division of Medical Sciences, Nation
AuthorAffiliation_xml – name: Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610%Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610;Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610;Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Department of Urology, Singapore General Hospital, Singapore 169610;Department of Surgery, Sengkang General Hospital, Singapore 544886%Department of Urology, Singapore General Hospital, Singapore 169610%Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857;Division of Medical Oncology, National Cancer Centre Singapore,Singapore 169610%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610;Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857;Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore
– name: 5 Department of Urology, Singapore General Hospital, Singapore 169610
– name: 7 Division of Medical Oncology, National Cancer CentreSingapore, Singapore 169610
– name: 6 Department of Surgery, Sengkang General Hospital, Singapore 544886
– name: 1 Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
– name: 2 Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610
– name: 3 Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
– name: 4 Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
– name: 8 Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore
Author_xml – sequence: 1
  givenname: Janice S H
  surname: Tan
  fullname: Tan, Janice S H
– sequence: 2
  givenname: Charles X Y
  surname: Goh
  fullname: Goh, Charles X Y
– sequence: 3
  givenname: Yen Sin
  surname: Koh
  fullname: Koh, Yen Sin
– sequence: 4
  givenname: Youquan
  surname: Li
  fullname: Li, Youquan
– sequence: 5
  givenname: Jeffrey K L
  surname: Tuan
  fullname: Tuan, Jeffrey K L
– sequence: 6
  givenname: Eu Tiong
  surname: Chua
  fullname: Chua, Eu Tiong
– sequence: 7
  givenname: Terence W K
  surname: Tan
  fullname: Tan, Terence W K
– sequence: 8
  givenname: Michael L C
  surname: Wang
  fullname: Wang, Michael L C
– sequence: 9
  givenname: Lui Shiong
  surname: Lee
  fullname: Lee, Lui Shiong
– sequence: 10
  givenname: Kae Jack
  surname: Tay
  fullname: Tay, Kae Jack
– sequence: 11
  givenname: Ravindran
  surname: Kanesvaran
  fullname: Kanesvaran, Ravindran
– sequence: 12
  givenname: Chee Keong
  surname: Toh
  fullname: Toh, Chee Keong
– sequence: 13
  givenname: Aaron K T
  surname: Tong
  fullname: Tong, Aaron K T
– sequence: 14
  givenname: Winnie W C
  surname: Lam
  fullname: Lam, Winnie W C
– sequence: 15
  givenname: Melvin L K
  surname: Chua
  fullname: Chua, Melvin L K
BookMark eNpVkdtu1DAQhiNURA_0HSxxAxfZ-pSsfYO0WpW2UhGVWK6tiT0bvDj2EidU7SPw1Bi2IOobz4xnvl-_57Q6iiliVb1hdMGp0vxit_A5x5LophZashIxtaBcqRfVyb_q0X_xcXWe846Wo5RopXpVHQvGmKZNe1L9bNUVhODnoQ7QYQjoyN3nj6v67nJzsd4QyASI89DHlCdvCURHbPDRWwjEofXZp1gP8M3HnkwpBeIjWWUPkezHMgITEgvR4kj2MHmMUybbFEK6_z3wt8VOaXh4Xb3cQsh4_nSfVV8-XG7W1_Xtp6ub9eq2dkypttaCdxwa0I4K7CSgcK1WFmSnpAUQrUKGS4Zb4Jajoku-5FRSTjuw0motzqqbA9cl2Jn96AcYH0wCb_4U0tgbGIvXgMY5tXSy6VTRko4WnaJavhEa26DoXGG9P7D2czegs8XfCOEZ9PlL9F9Nn36YtuFKSlEA7w6Ae4hbiL3ZpXmMxb557B9DsAbLfjVllLWl9-2T2Ji-z5gnM_hsy84gYpqz4VxwxtmycH8BoButeQ
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright 2019 Cancer Biology & Medicine 2019
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
– notice: Copyright 2019 Cancer Biology & Medicine 2019
DBID 7X8
2B.
4A8
92I
93N
PSX
TCJ
5PM
DOA
DOI 10.20892/j.issn.2095-3941.2018.0288
DatabaseName MEDLINE - Academic
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2095-3941
EndPage 166
ExternalDocumentID oai_doaj_org_article_dd87d45b8d034d06989d0088a5c5e3bd
zgzllc_e201901016
GrantInformation_xml – fundername: This work was supported in part by Varian,Paolo Alto,CA through a structured research agreement.MC is supported by the National Medical Research Council Singapore Clinician-Scientist Award(Grant NMRC/CSA/0027/2018); the Duke-NUS Oncology Academic Program Proton Research Program.This work was presented in part at the ESMO Asia Congress 2017 and ASCO GU Symposium 2018
GroupedDBID -05
-0E
-SE
-S~
2B.
2C~
5VR
7X8
8FE
8FH
92F
92I
92M
93N
93R
9D9
9DE
AAKDD
AAXDM
ABDBF
ABKZE
ABUWG
AFKRA
AFUIB
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVBZV
CAJEE
CCEZO
CCPQU
CHBEP
CIEJG
DIK
EBD
EOJEC
ESX
FA0
GROUPED_DOAJ
HCIFZ
HYE
JUIAU
KQ8
LK8
M48
M7P
OBODZ
OK1
PGMZT
PIMPY
PQQKQ
PROAC
Q--
Q-4
R-E
RNS
RPM
RT5
S..
T8U
TCJ
TGQ
U1F
U1G
U5E
U5O
WFFXF
~N8
4A8
ADRAZ
CAJUS
MET
PSX
5PM
ID FETCH-LOGICAL-d1886-932b2a5a9d03eb4ae3d698ca4b84caa368e1e71efa2c2e80727204020bac4c993
IEDL.DBID RPM
ISSN 2095-3941
IngestDate Fri Oct 04 13:14:58 EDT 2024
Tue Sep 17 21:13:31 EDT 2024
Tue Feb 13 23:42:11 EST 2024
Fri Aug 16 21:04:53 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords recurrence
prostate cancer
salvage radiotherapy
prostatectomy
diagnostic
Asian
68Ga PSMA PET/CT
Language English
License This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-d1886-932b2a5a9d03eb4ae3d698ca4b84caa368e1e71efa2c2e80727204020bac4c993
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528443/
PMID 31119056
PQID 2232121744
PQPubID 23479
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_dd87d45b8d034d06989d0088a5c5e3bd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6528443
wanfang_journals_zgzllc_e201901016
proquest_miscellaneous_2232121744
PublicationCentury 2000
PublicationDate 20190201
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 2
  year: 2019
  text: 20190201
  day: 1
PublicationDecade 2010
PublicationPlace Tianjing China
PublicationPlace_xml – name: Tianjing China
PublicationTitle Cancer biology & medicine
PublicationTitle_FL Cancer Biology & Medicine
PublicationYear 2019
Publisher Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610%Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610
Department of Surgery, Sengkang General Hospital, Singapore 544886%Department of Urology, Singapore General Hospital, Singapore 169610%Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Department of Urology, Singapore General Hospital, Singapore 169610
Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore
Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
Division of Medical Oncology, National Cancer Centre Singapore,Singapore 169610%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
Chinese Anti-Cancer Association
China Anti-Cancer Association
Publisher_xml – name: Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610, Singapore
– name: Radiological Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
– name: Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
– name: Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610%Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore 169610
– name: Department of Surgery, Sengkang General Hospital, Singapore 544886%Department of Urology, Singapore General Hospital, Singapore 169610%Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857
– name: Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857%Department of Urology, Singapore General Hospital, Singapore 169610
– name: Division of Medical Oncology, National Cancer Centre Singapore,Singapore 169610%Division of Radiation Oncology, National Cancer Centre Singapore, Singapore 169610
– name: Chinese Anti-Cancer Association
– name: China Anti-Cancer Association
SSID ssj0000883648
Score 2.1650558
Snippet OBJECTIVEProstate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk stratification...
Objective:Prostate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts.There is no risk stratification...
Objective Prostate cancers (PCa) in Asian individuals are molecularly distinct from those found in their Caucasian counterparts. There is no risk...
SourceID doaj
pubmedcentral
wanfang
proquest
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 157
SubjectTerms 68Ga PSMA PET/CT
Asian
diagnostic
Original
prostate cancer
prostatectomy
recurrence
salvage radiotherapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSouiKdYKMg8rm6T2HHs41K1VEiLKrGVeovGjy2LsknV3VXV_gR-NTNOFu1y4cI1TpxkPtvzeTwPxj5pK10MGpmb8iCU91aAImeaQlWZcsFmhoKTJ9_02YX6ellebpX6Ip-wPj1wLziymlVBlc6ETKqQUb3DgHrLQOnLKF1Iq29ebm2m0hpsjNSpdFaBHEJIq_J99pH8njNji6OfaYYd_mkjFy9ziKrWDKn7d_jm396SD2-hnUF7taWITp-wxwOD5OP-y5-yB7F9xvYnwxn5c_ZLmy_QNPP1QiDCZJcP_Pz7ZCzOT6ZHx1MOSw489B522AWHNvBNfCQPQ8kdsUhVqviq6xo-b_mYYi35NYWIIDnlnsbKDR-Ssi75DEdTd0sPbG7xq25x94JdnJ5Mj8_EUHFBhNwYLZDMuQJKQBHL6BREGVDgHpQzCCVIbWIeqzzOoPBFNFk6xaUdqAOvPFKdl2yv7dr4ivHKKe2lKkPpA2IenbURrIeQWcit0SP2mQRdX_dJNWpKc50uIPj1AH79L_BH7P0GphqnBZ11QBu79bJG1oNKGbdbasSqHfx23rjb0s5_pATbukSlreSIfRiQroeJvazvr-6bxtexoBh8sny8_h__8YY9og57b_ADtre6Wce3SHZW7l0a178BY13-bw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZKERUXxCqmLDLLNW0SO459QGioWiqkQZWYkXqLnpcZBmWSdhaV9ifwq3kv40EM4sCBYxY7id_34u_Zb2HsrTLCBq-QuUkHiXTOJCDJmSaXZSqtN6mm4OTBZ3U6kp_Oi_MdtklPEAdw8VfTjupJjeb1wffL6_eo8O_IjTnVJj_81ikMHpgiEUaS2ZfpA5w59S12O5dCEvQHkfd3v2itheoqa_1qs8fe_EN_MbP_Fh3905nyzhU0Y2gmv81TJ_fZvUgweX-NiAdsJzQP2d4gbqE_Yj-U_gh1PV3NEgQALdt7fvZl0E_OjoeHR0MOCw7crx3wsAsOjeeb8EnuY0WeZNYVseLLtq35tOF9CsXkFxRBgtyVO4LSnMecrQs-RrC1V9Rgc4tbtrPrx2x0cjw8Ok1iQYbEZ1qrBLmezaEA41MRrIQgvDLagbQaJQ1C6ZCFMgtjyF0edNpt8pKBasFJh0zoCdtt2iY8Zby0UjkhC184j5AI1pgAxoFPDWRGqx77QANdXaxzblSUBbs70c4nVVSqyntdellYje8jfUq1MD3JFgpXBGF9j73aiKlCraGtEGhCu1pUSIpwzkZrTPZYuSW_rSduX2mmX7v826rAOV2KHnsdJV1tYFvdTG7q2lUhpxB9WhjZ_x_f8YzdpQ7XzuLP2e5yvgovkAst7csO1z8Bnl4I2w
  priority: 102
  providerName: Scholars Portal
Title 68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
URI https://search.proquest.com/docview/2232121744
https://d.wanfangdata.com.cn/periodical/zgzllc-e201901016
https://pubmed.ncbi.nlm.nih.gov/PMC6528443
https://doaj.org/article/dd87d45b8d034d06989d0088a5c5e3bd
Volume 16
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECWSFA16KbqiTluDXa6yFlIUebRdu0EBBUbrALkJ3Oy60GJ4QZB8Qr-6Q1oq4h57kQBRogi9ofhIvplB6DMTRFnDgLlRLQOqtQgkdWKahGYRVUZE3Dkn51fs8pp-u0lvTlDa-cJ40b5Wq0FdVoN69dNrK9eVDjudWDjLxyyFnyol4Sk6zQh5MEX3v1_OCfNZsxKgDwERND5Hn5zkOeIiCX_5zjX4W-bUXXwAo6zL3Eeg54so7QL4H7HOfzWTj29lvZD18sFwNH2GnrY8Eg8P7X2OTmz9Ap3n7U75S_Sb8a-yLFf7KgCc3eq8wbMf-TCYTebheI7lFktsDjo7qALL2uDOSxKbNvFOUPlcVXjXNCVe1XjoPC7x2jmKAEXF2lnMBrehWbd4ATbV3LoHulv0rqnuXqHr6WQ-vgzavAuBiTlnAVA6lchUChMRq6i0xDDBtaSKA6CSMG5jm8V2IROdWB75vVw3D1VSUw2E5zU6q5vavkE4U5RpQlOTagPIWyWElUJLEwkZC856aOQ-dLE-hNYoXLBrf6HZLIsW8sIYnhmaKg7toSZyKS-Ng1mmOrVEmR760MFUQOdwOx6yts1-WwD3gaEZJl20h7Ij_I7eeFwCVufDbLdW1kMfW6SLtntvi_vlfVnqwibOE9-tf1z8d_Vv0RNXy0EI_g6d7TZ7-x54zk710aPh6MtoCufR5Gr2ve_XC-CYU973Nv8HgZ4DnA
link.rule.ids 230,315,733,786,790,870,891,2115,2236,24346,27955,27956,33778,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jj9MwFLaGQQxc2BFlNcs1u-3ax1LNUGAyqkQHzS3y1lLIUrWpRvQn8Kt5zoKmc4NrnDhx_D37s_299xB6z0SirGHA3IiWHtFaeJI4MU1MhiFRRoTcOSenZ2xyTj5f0IsDRHtfmEa0r9XSL_PCL5ffG23lqtBBrxMLpumYURhUSRLcQDfBXmN6ZZHeDMCcJ6zJmxUDgfASQaIj9M6JnkMu4uBHY17-3zKn7-I-zLMud18Cti9C2ofw3-Od11WTty5lOZfl4sqEdHIPfeub0upQfvrbWvl6dy3K4z-39T6621FUPGqLH6ADWz5ER2l3CP8I_Wb8o8zz5bbwAEJu49_g6dd05E2PZ8F4huUGS2xaCR9UgWVpcO-AiU2X08crmjRYuK6qHC9LPHLOnHjlfFCA_WLtwLjGXdTXDZ4DXKtL90B_i66r4tdjdH5yPBtPvC6lg2cizpkHbFHFkkphwsQqIm1imOBaEsUBKzJh3EZ2GNm5jHVsedgcE7slrpKaaOBST9BhWZX2KcJDRZhOCDVUGwCVVUJYKbQ0oZCR4GyAPrgezFZt1I7MxdFuLlTrRdb94cwYPjSEKg7fQ0zosmkahx9JNbWJMgP0pu__DOzOHabI0lbbTQa0CmZ9WM-RARruAWPvjfsl0MlNBO-uUwfobQehrBs5NtlusctzndnYOfm7rZVn_139a3R7MktPs9NPZ1-eozuuxlZv_gId1uutfQl0qlavGuP5A7MVILc
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXaFDV66V7UXdnlqp2iyKPrxk0XBwbqAEEvBDe7TrQYtoyg_oR-dYeyVNg55ipSlCi-IR_FNzMIfaQ8UdZQYG5ES49ozT1JnJgmJllIlOEhc87J41N6cka-nafne6m-GtG-Vgu_zAu_XPxutJXLQgedTiyYjIc0hUmVJMHSzILb6A7YbJztbdSbSZixhDa5s2IgEV7CSdRDH5zwOWQ8Di4aE_P_lzmNF_NhrXX5-xKwfx6mXRj_A-55XTl590qWM1nO9xal0QP0q-vOToty6W9q5evttUiPN-rvQ3S_pap4sKvyCN2y5WPUG7eH8U_QX8q-yDxfbAoPoOQOAAye_BwPvMnxNBhOsVxjic1OygdNYFka3DliYtPm9vGKJh0Wrqsqx4sSD5xTJ146XxRgwVg7UK5wG_11jWcA2-rK3dBV0XVV_HmKzkbH0-GJ16Z28EzEGPWANapYppKbMLGKSJsYypmWRDHAjEwos5HNIjuTsY4tC5vjYrfVVVITDZzqGToqq9I-RzhThOqEpCbVBsBlFedWci1NyGXEGe2jT24UxXIXvUO4eNrNhWo1F-1XFsawzJBUMXgfYkKXVdM4DMlUpzZRpo_edRgQYH_uUEWWttqsBdArWP1hX0f6KDsAx8ETD0tgoJtI3u3A9tH7FkainUHWYjvf5rkWNnbO_u4Xy4sbN_8W9SafR-LH19PvL9E91-BOdv4KHdWrjX0NrKpWbxr7-QehwyM3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=68Gallium-labelled+PSMA-PET%2FCT+as+a+diagnostic+and+clinical+decision-making+tool+in+Asian+prostate+cancer+patients+following+prostatectomy&rft.jtitle=Cancer+biology+%26+medicine&rft.au=Janice+S.H.+Tan&rft.au=Charles+X.Y.+Goh&rft.au=Yen+Sin+Koh&rft.au=Youquan+Li&rft.date=2019-02-01&rft.pub=China+Anti-Cancer+Association&rft.issn=2095-3941&rft.eissn=2095-3941&rft.volume=16&rft.issue=1&rft.spage=157&rft.epage=166&rft_id=info:doi/10.20892%2Fj.issn.2095-3941.2018.0288&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_dd87d45b8d034d06989d0088a5c5e3bd
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgzllc-e%2Fzgzllc-e.jpg